Cartography Biosciences and Samsung Ventures today announced a strategic investment to support the advancement of Cartography’s differentiated oncology pipeline and expand its proprietary drug discovery platform.

Cartography Biosciences和三星风险投资公司今天宣布了一项战略投资，以支持Cartography差异化的肿瘤学管线的进展，并扩展其专有的药物发现平台。

The investment was made through the Samsung Life Science Fund, established by Samsung Biologics (KRX: 207940.KS), Samsung Bioepis, and Samsung C&T, and managed by Samsung Ventures. The fund focuses on innovative biopharmaceutical companies developing next-generation technologies across modalities, including biologics, gene editing, and AI-enabled therapeutics..

通过三星生物基金（Samsung Life Science Fund）进行投资，该基金由三星生物制药（Samsung Biologics，韩国证券交易所代码：207940.KS）、三星Bioepis和三星物产（Samsung C&T）共同设立，并由三星风险投资公司（Samsung Ventures）管理。该基金专注于开发跨多种模式的下一代技术的创新型生物医药公司，包括生物制品、基因编辑和人工智能驱动的治疗药物。

Together, Cartography Biosciences and Samsung Ventures aim to accelerate the development of novel cancer therapies by leveraging Cartography’s antigen discovery and drug development capabilities alongside Samsung’s global expertise in life sciences investment and strategic development.

Cartography Biosciences 与三星风险投资公司携手，旨在通过结合 Cartography 的抗原发现和药物开发能力，以及三星在全球生命科学投资和战略发展方面的专业知识，加速新型癌症疗法的开发。

“Samsung Ventures is an ideal partner as we continue to advance our mission of precisely mapping tumor biology to develop highly differentiated antibody-based therapies,” said Kevin Parker, Chief Executive Officer of Cartography Biosciences. “We are excited to partner with a global leader that recognizes the value of new technologies and cutting-edge biologic engineering in the discovery of novel biopharmaceuticals.”.

“Samsung Ventures是我们继续推进精确绘制肿瘤生物学以开发高度差异化的基于抗体的疗法这一使命的理想合作伙伴，”Cartography Biosciences首席执行官Kevin Parker表示。“我们很高兴能与一位全球领导者合作，他们认识到新技术和前沿生物工程在发现新型生物制药中的价值。”

“Cartography Biosciences represents a new generation of biotechnology innovation, combining large-scale data, computational biology, and therapeutic design to unlock novel cancer therapies,” said Dr. Joseph Jeong, Executive Vice President, and Head of Bio R&D Center at Samsung Biologics. “This investment reflects our commitment to supporting innovative technologies with the potential to transform treatment paradigms and deliver meaningful impact to patients worldwide.”.

“Cartography Biosciences 代表了新一代的生物技术创新，结合大规模数据、计算生物学和治疗设计，以解锁新型癌症疗法，”三星生物制药公司执行副总裁兼生物研发中心负责人Joseph Jeong博士表示。“这项投资体现了我们致力于支持具有转变治疗模式潜力的创新技术，并为全球患者带来有意义的影响。”

Cartography’s ATLAS and SUMMIT platforms integrate proprietary single-cell datasets with advanced computational biology and target validation capabilities to identify tumor-restricted antigens and antigen combinations. This approach enables the design of antibody therapeutics with improved specificity and therapeutic index..

Cartography的ATLAS和SUMMIT平台将专有的单细胞数据集与先进的计算生物学和靶点验证能力相结合，以识别肿瘤限制性抗原和抗原组合。这种方法能够设计出具有更高特异性和治疗指数的抗体疗法。

Cartography is advancing a pipeline of oncology programs aimed at addressing significant unmet medical needs. Its lead program, CBI-1214, a T-cell engager for colorectal cancer, entered the clinic in early 2026 and is currently enrolling patients in a Phase 1 clinical trial.

Cartography正在推进一条肿瘤学项目管线，旨在满足显著未被满足的医疗需求。其主要项目CBI-1214是一种用于结直肠癌的T细胞结合剂，于2026年初进入临床，并正在一期临床试验中招募患者。

About Cartography Biosciences

关于卡托格拉菲生物科学

Cartography Biosciences is advancing a differentiated oncology pipeline of antibody-based therapies designed to target tumors with unprecedented precision. The company’s ATLAS and SUMMIT discovery platforms are powered by an industry-leading, fully integrated dataset spanning hundreds of thousands of cell states across healthy tissues alongside large-scale single-cell profiling of patient tumors.

Cartography Biosciences正在推进一条差异化的肿瘤学抗体治疗管道，旨在以前所未有的精确度靶向肿瘤。该公司的ATLAS和SUMMIT发现平台由行业领先的、完全集成的数据集提供支持，该数据集涵盖健康组织中的数十万种细胞状态，并对患者肿瘤进行大规模单细胞分析。

By combining petabyte-scale proprietary data, machine learning, and AI-driven biological insights, Cartography is identifying highly specific tumor targets and logic-gated target combinations to generate therapies engineered for maximal tumor selectivity and meaningful patient impact. The company’s lead program, CBI-1214, is a T-cell engager in development for colorectal cancer.

通过结合千万亿字节规模的专有数据、机器学习和人工智能驱动的生物学洞察，Cartography正在识别高度特异性的肿瘤靶点以及逻辑门控的靶点组合，以开发具有最大肿瘤选择性和对患者有意义影响的疗法。该公司的主要项目CBI-1214是一种正在开发中的T细胞接合器，用于治疗结直肠癌。

CBI-1214 entered the clinic in early 2026 and is currently enrolling and treating patients in a phase 1 trial..

CBI-1214于2026年初进入诊所，目前正在1期试验中招募和治疗患者。

About Samsung Ventures

三星风险投资公司简介

Samsung Venture Investment Corporation was established to promote promising small and medium-sized companies engaging in the development of new technologies. The Samsung Ventures collaboration is based on managerial and scientific know-how, actively investing in future-oriented businesses based on new and innovative technologies that are expected to serve as new growth engines.

三星创业投资公司旨在促进从事新技术开发的有前途的中小型企业的发展。三星创投的合作基于管理与科学的专业知识，积极投资于那些有望成为新的增长动力的、基于新颖创新技术的前瞻性业务。

More information is available by visiting the Samsung Ventures website at: https://www.samsungventure.co.kr/en/main.do.

更多信息可访问三星风险投资公司网站获取：https://www.samsungventure.co.kr/en/main.do。

Contacts

联系人

Media Contacts

媒体联系人

Cartography Biosciences

生物科学制图学

Ashlea Kosikowski

阿什莉娅·科西科夫斯基

ashlea@1abmedia.com

ashlea@1abmedia.com

Source: businesswire.com

来源：businesswire.com